TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05500417
Drug: ALFQ
Normalized name: ALFQ component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALFQ (Army Liposome Formulation containing QS-21) is composed of ALF55 (cGMP-manufactured Army Liposome Formulation), QS-21 (purified extracted saponin), and Sorensen's Phosphate Buffer. Full dose of AFLQ compromised of 200 microgram 3D-PHAD and 100 microgram QS-21, co-administered with main intervention.
Study: NCT06763341
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT06763341
Drug: PCNA Inhibitor AOH1996
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06763341
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06578507
Drug: Hydroxycarbamid
Normalized name: Hydroxycarbamid
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxycarbamide Paediatric dispersible tablets will be provided in the form of film-coated dispersible tablets containing 50 mg of hydroxycarbamide.~The IMP will be administered as half-strength twice daily, based on the body weight of the patient.
Study: NCT04517435
Drug: ME-401
Normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
DrugBank: Lactobacillus fermentum (DB16542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ME-401 (60 mg) will be given by mouth every 21 days for 6 cycles on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle. Dose escalation will be performed in a standard 3+3 design
Study: NCT04517435
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 IV/subcutaneous rituximab day 1 of 21-day cycle.~First dose of rituximab will be given IV and subsequent doses can be either IV or SQ based on institutional guidelines.
Study: NCT04517435
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4 mg/m2 (max 2 mg) IV Vincristine
Study: NCT04517435
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg PO Prednisone Days 1-5 of 21-day cycle
Study: NCT04194424
Drug: Metformin Hcl 850Mg Tab
Normalized name: METFORMIN HCL 850MG TAB
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 tablet, twice daily
Study: NCT06782087
Drug: nano chitosan
Normalized name: Chitosan
DrugBank: Chitosan low molecular weight (20-200 mpa.s) (DB14155)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nano chitosan
Study: NCT06780111
Drug: Levoleucovorin
Normalized name: Levoleucovorin
DrugBank: Levoleucovorin (DB11596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/m\^2 via IV infusion
Study: NCT06780111
Drug: 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2 bolus followed by 2400 mg/m\^2 continuous IV infusion for 48 hours
Study: NCT06780111
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85mg/m\^2 via IV infusion
Study: NCT06780787
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06654947
Drug: Surufatinib+Toripalimab+GEMOX
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib (200mg，qd，Q3W）；Toripalimab(240mg IV d1, Q3W)；GEMOX：Gemcitabine: 1000 mg/m2, IV，d1，d8，Q3W，Oxaliplatin：100mg/m2,ivgtt，d1，Q3W）
Study: NCT06774313
Drug: ABBV-142
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT06774313
Drug: ABBV-142
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) Injection
Study: NCT05008276
Drug: Aminohippurate Sodium Inj 20%
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Study: NCT05008276
Drug: Iohexol Inj 300 MG/ML
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Study: NCT05008276
Drug: Dextran 40
Normalized name: Dextran 40
DrugBank: Dextran (DB09255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic aid/agent used to measure glomerular size and selectivity
Study: NCT06618976
Drug: Sotagliflozin
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Sotagliflozin 400 mg, P.O. once daily for 1 month.
Study: NCT06618976
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 10 mg, P.O. once daily for 1 month.
Study: NCT06675955
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab will be administered according to the regimen in the parent study.
Study: NCT04520217
Drug: 4% Imipramine Cream
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4% Imipramine Cream
Study: NCT04520217
Drug: Base Cream
Normalized name: U-Base Cream
DrugBank: K201 free base (DB02929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base Cream
Study: NCT06284941
Drug: Ropivacaine combined with methylene blue for iliac fascia block
Normalized name: Methylene Blue
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound guided iliac fascia block, administered with 30ml of 0.25% ropivacaine+0.05% methylene blue
Study: NCT06470542
Drug: 2 x 20 ml of Ropivacaine 0.2% Injectable Solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 x 20ml 0.2% Ropivacaine - ultrasound-guided iPACK + ACB
Study: NCT06470542
Drug: 2 x 20ml of Ropivacaine 0.2% Injectable Solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 x 20ml 0.2% ropivacaine - ultrasound-guided ESPB at the L1 and S1 level
Study: NCT06349473
Drug: SR604
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SR604 will be administered as SC injection.
Study: NCT05661682
Drug: Tralement
Normalized name: Tralement
DrugBank: Manganese cation (DB06757)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralement with Manganese Sulfate
Study: NCT04729387
Drug: Alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpelisib will be administered at 200 mg orally once daily following food on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle
Study: NCT04729387
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib will be administered at 200 mg orally twice daily irrespective of meals on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle.
Study: NCT04729387
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered at 80 mg/m2 as an intravenous infusion weekly during a 28-day treatment cycle, starting on Cycle 1 Day 1, and on Day 8, Day 15 and Day 22 of every cycle thereafter
Study: NCT04847453
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04847453
Drug: Ixazomib Citrate
Normalized name: Ixazomib citrate
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05071352
Drug: Nefopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours.
Study: NCT04847453
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04086485
Drug: Lu-177-DOTATATE
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu-177-DOTATATE will be given by IV every 8 (+/-2) weeks for a total of 4 administrations
Study: NCT04086485
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib is given as a pill taken orally and is to be taken twice a day, starting from 2 days before the first administration of Lu-177-DOTATATE until 4 weeks after the last administration
Study: NCT04086485
Drug: Amino Acid infusion
Normalized name: silk amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection. The AA infusion will begin at least 30-60 minutes prior to injection of Lu-177-DOTATATE and will continue during and after the Lutathera infusion until the entire prescribed amount is infused.
Study: NCT04779697
Drug: GLP-1 analogue - semaglutide
Normalized name: Glucagon-like peptide-1 (GLP-1) analogues
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: GLP-1 analogue - semaglutide - administered once weekly for a total of 12 weeks
Study: NCT04652960
Drug: Duvelisib
Normalized name: Duvelisib
DrugBank: Duvelisib (DB11952)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT05554354
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05554354
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IM
Study: NCT05602636
Drug: bupivacaine, midazolam
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be provided with midazolam (up to 2 mg) if requested. No opioids will be administered before the incision. At the first patient complaint of pain, the intraoperative anesthesia team will document the quality and location of pain, and 50 microgram of fentanyl will be administered if the patient requested it or pain score more than 3
Study: NCT05777226
Drug: Epalrestat
Normalized name: Epalrestat
DrugBank: Epalrestat (DB15293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the treatment group are intervened with Epalrestat tablets.
Study: NCT06704191
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intravesically
Study: NCT06704191
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravesically
Study: NCT06704191
Drug: Mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intravesically
Study: NCT06734273
Drug: Mounjaro
Normalized name: Mounjaro
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide after surgery. Patients who were selected in this arm will undergo a 4-week dose escalation period. Starting at 6 months they will receive weekly 2.5mg doses (for 4 weeks). Afterwards, they will receive weekly 5mg doses. They will maintain this dose until 12 months after surgery.
Study: NCT06609005
Drug: INV-9956
Normalized name: INV-REMDESIVIR
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: INV-9956 is co-administered with dexamethasone and fludrocortisone acetate
Study: NCT05849298
Drug: Piflufolastat F 18
Normalized name: piflufolastat F 18
DrugBank: Piflufolastat F 18 (DB14805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of approx. 333 Megabecquerel (MBq) prior PSMA-PET scans
Study: NCT05849298
Drug: ARPI
Normalized name: Akarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enzalutamide, Darolutamide, Apalutamide as prescribed by the local investigator
Study: NCT04533646
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be asked to dose insulin during the first week using fixed doses. During the second week of the study, participants will dose insulin based on carbohydrate counting. Blood sugar control will be compared between the 2 weeks to determine the outcomes of the study.
Study: NCT06234631
Drug: Epidiolex oral solution
Normalized name: Epidiolex
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants assigned to CBD will take the medication one hour before or two hours after eating a meal.~If participants can't tolerate the full-strength dose, the participant can decrease the dosing to 0.75 milliliter twice a day. If this is still not well tolerated, dosing can further be decreased to 0.75 milliliter once per day in the evening.
Study: NCT05197530
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A trained physician will inject 0.1 ml of the ICG in to the web spaces of the hands in both upper extremities.
Study: NCT06091124
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab 1200 mg IV on Day 1, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
Study: NCT06091124
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 0.1g IV on Days 1-3, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
Study: NCT06091124
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 35mg/m2 IV on Days 1-2, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
Study: NCT06773026
Drug: Sodium phenylbutyrate
Normalized name: Sodium Phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label design with doses of sodium phenylbutyrate at 4.0 g/m2/day
Study: NCT05571839
Drug: PF-08046049
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given into the vein (IV; intravenous)
Study: NCT06063746
Drug: Vidutolimod
Normalized name: Vidutolimod
DrugBank: Vidutolimod (DB17500)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05252390
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib
Study: NCT05252390
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide
Study: NCT06648031
Drug: Arm 1 - DehydraTECH-CBD alone
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose: 250 mg CBD twice daily (500 mg/day) for 12 weeks. Route of administration: Oral Dosage form: Capsule
Study: NCT06648031
Drug: Arm 2 - DehydraTECH-semaglutide alone
Normalized name: semaglutide 2 MG/ML
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose: 3.5 mg once daily for 4 weeks, ascending to 7 mg once daily for the remaining 8 weeks. Route of administration: Oral Dosage form: Capsule
Study: NCT06648031
Drug: Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide
Normalized name: semaglutide 3 MG
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: DehydraTECH-CBD dosing = 250 mg twice daily for 12 weeks.~- DehydraTECH-semaglutide = 3.5 mg once daily for 12 weeks Route of administration: Oral Dosage form: Capsule
Study: NCT06648031
Drug: Arm 4 - Rybelsus medication (semaglutide) alone
Normalized name: semaglutide 4 MG [Rybelsus]
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Normal clinical dose of 3.0 mg once daily for 4 weeks, ascending to 7.0 mg once daily for the remaining 8 weeks. Route of administration: Oral Dosage form: Capsule
Study: NCT06648031
Drug: Arm 5- Tirzepatide
Normalized name: tirzepatide 5 MG/ML
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tirzepatide arm - 20mg for 4 weeks and then 40mg for 8 weeks
Study: NCT05983198
Drug: 225Ac-PSMA-R2
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSMA-R2 is a ligand coupled with 225Ac an alpha emitting radionuclide
Study: NCT05062980
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody indicated for treatment of patients with metastatic NSCLC.
Study: NCT05062980
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel is a microtubule inhibitor indicated for locally advanced or metastatic NSCLC after platinum-based chemotherapy failure.
Study: NCT05062980
Drug: ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated in combination with docetaxel for treatment of NSCLC with disease progression after platinum-based chemotherapy.
Study: NCT04965155
Drug: Isatuximab-dexamethasone
Normalized name: Isatuximab
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Isatuximab 10 mg/kg IV: 1,8,15 and 22 at cycle 1; days 1 and 15 at cycles 2-3 Dexamethasone 40 mg OS: 1,8,15 and 22 at cycle 1; days 1 and 15 at cycles 2-3
Study: NCT05525572
Drug: Autologous Platelet-Rich Plasma (PRP)
Normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Platelet Rich Plasma (PRP):~5 mL PRP will be administered via intra-cavernous penile injection with a 30 ± 7 day treatment interval.
Study: NCT05607004
Drug: (Z)-endoxifen
Normalized name: Z-160
DrugBank: Z-160 (DB12743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Z)-endoxifen capsules. Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).
Study: NCT05607004
Drug: exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: exemestane tablets 25 mg
Study: NCT05607004
Drug: goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: goserelin 3.6 mg subcutaneous implant
Study: NCT05111600
Drug: Transplantation
Normalized name: Transplantation antigen
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantation of autologous cultured grafts containing genetically modified stem cells for restoration of functional skin on pre-selected areas
Study: NCT06523556
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV or SC
Study: NCT06430580
Drug: Yohimbine Hydrochloride
Normalized name: Yohimbine Hydrochloride
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 54mg yohimbine hcl, single oral dose
Study: NCT06430580
Drug: Cornstarch Placebo 20mg
DrugBank: Corn (DB10572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg cornstarch placebo, single oral dose
Study: NCT06430580
Drug: Cornstarch Placebo 54mg
DrugBank: Corn (DB10572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 54mg cornstarch placebo, single oral dose
Study: NCT05339490
Drug: Progenitor Biological Bandages
Normalized name: human cord blood hematopoietic progenitor cell
DrugBank: Human cord blood hematopoietic progenitor cell (DB11054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, PBB will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1. Old PBB will be replaced by new ones according to the local procedure.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality.
Study: NCT06235411
Drug: Psilocybin therapy
Normalized name: Monistat Simple Therapy
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two administrations of psilocybin given 3 weeks apart. The treatment day will begin around 9 a.m. with a brief interview. Patients will be invited to relax and music will be played through speakers and headphones.~One 25 mg capsule of Psilocybin will be given approximately 30 minutes to 1.5 hours later.~The patient is accompanied throughout the session (minimum 6 hours depending on the effects felt). The patient will benefit from a preparation session the day before dosing, and an integration session the day after. Intensive relapse prevention program will be dispensed between the 2 dosing sessions (treatment as usual).
Study: NCT06235411
Drug: Inactive Psilocybin therapy
Normalized name: Monistat Simple Therapy
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two administrations of psilocybin given 3 weeks apart. The treatment day will begin around 9 a.m. with a brief interview. Patients will be invited to relax and music will be played through speakers and headphones.~One 1 mg capsule of Psilocybin will be given approximately 30 minutes to 1.5 hours later.~The patient is accompanied throughout the session (minimum 6 hours depending on the effects felt). The patient will benefit from a preparation session the day before dosing, and an integration session the day after. Intensive relapse prevention program will be dispensed between the 2 dosing sessions (treatment as usual).
Study: NCT04950764
Drug: Seladelpar 10 mg
Normalized name: seladelpar 10 MG
DrugBank: Seladelpar (DB12390)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seladelpar 10 mg single oral dose
Study: NCT04950764
Drug: Seladelpar 10 mg or less
Normalized name: seladelpar 10 MG
DrugBank: Seladelpar (DB12390)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seladelpar 10 mg or less, once daily for 28 days